Abstract:Efforts to develop biomarker-targeted anti-cancer therapies have progressed rapidly in recent years. Six antibodies acting on programmed death ligand 1 or programmed death 1 pathways were approved in 75 cancer indications between 2015 and 2021. With efforts to expedite regulatory reviews of promising therapies, several targeted cancer therapies have been granted accelerated approval on the basis of single-arm phase II trials. And yet, in the absence of randomization, patient outcomes may not have been studied under standard of care chemotherapies for emerging biomarker subpopulations prior to the submission of an accelerated approval application. Historical control rates used in single arm studies often arise as population averages, lacking specificity to the targeted subgroup. For example, a recent phase III trial of atezolizumab in patients with metastatic urothelial carcinoma found a 21.6% response rate to standard of care chemotherapy in the biomarker subgbroup of interest, much higher than the historical control rate of 10% that had been used to declare success in the preceding phase II trial. Innovations in design methodology are needed to enable efficient implementation of randomized trials for agents that target biomarker subpopulations. This article proposes three randomized designs for early phase biomarker-guided oncology clinical trials. Each design utilizes the optimal efficiency predictive probability method to monitor multiple biomarker subpopulations for futility. A simulation study motivated by the results reported in the atezolizumab trial is used to evaluate the operating characteristics of the various designs. Our findings suggest that efficient statistical design can be conducted with randomization and futility stopping to effectively acquire more evidence pertaining to comparative efficacy before deciding to conduct a phase III confirmatory trial.

Optimal predictive probability designs for randomized biomarker-guided oncology trials

Optimal Biomarker-Guided Design for Targeted Therapy with Imperfectly Measured Biomarkers

Optimal Marker-Adaptive Designs for Targeted Therapy Based on Imperfectly Measured Biomarkers

Randomized Phase II Cancer Clinical Trials to Validate Predictive Biomarkers

Optimal Marker-Strategy Clinical Trial Design to Detect Predictive Markers for Targeted Therapy

Lessons Learned from Implementing a Novel Bayesian Adaptive Dose-Finding Design in Advanced Pancreatic Cancer.

Biomarker-Driven Oncology Trial Design and Subgroup Characterization: Challenges and Potential Solutions

A Bayesian Group Sequential Design for Randomized Biosimilar Clinical Trials with Adaptive Information Borrowing from Historical Data

Adaptive designs for identifying optimal biological dose for molecularly targeted agents.

Hybrid Design Evaluating New Biomarkers when There is an Existing Screening Test

Subgroup-Based Adaptive (SUBA) Designs for Multi-arm Biomarker Trials

Model-based meta-analysis of non-small cell lung cancer with standard of care PD-1 inhibitors and chemotherapy for early development decision making

A Bayesian Dose Finding Design for Oncology Clinical Trials of Combinational Biological Agents

Optimal Sequential Enrichment Designs for Phase II Clinical Trials.

Design and Reporting of Phase III Oncology Trials with Prospective Biomarker Validation.

A signature enrichment design with Bayesian adaptive randomization

An Adaptive Trial Design to Optimize Dose-Schedule Regimes with Delayed Outcomes

Biomarker enrichment strategies: matching trial design to biomarker credentials

Bayesian Optimal Interval Design: A Simple and Well-Performing Design for Phase I Oncology Trials.

Assessing clinical response in early oncology development with a predictive biomarker

Adaptive phase I–II clinical trial designs identifying optimal biological doses for targeted agents and immunotherapies